作者: J H Edmonson , L M Ryan , R H Blum , J S Brooks , M Shiraki
DOI: 10.1200/JCO.1993.11.7.1269
关键词: Survival analysis 、 Doxorubicin 、 Sarcoma 、 Chemotherapy 、 Toxicity 、 Cisplatin 、 Surgery 、 Urology 、 Ifosfamide 、 Medicine 、 Randomization
摘要: PURPOSEThis three-armed phase III study in adults with advanced soft tissue sarcomas was planned as a comparison of objective regression rates, toxicity, and survival patients receiving doxorubicin alone, ifosfamide plus doxorubicin, mitomycin cisplatin.PATIENTS AND METHODSBetween December 1987 July 1990, 279 histologically confirmed were enrolled to receive treatment A (doxorubicin 80 mg/m2), B (ifosfamide 7.5 g/m2 60 or C (mitomycin 8 mg/m2 40 cisplatin mg/m2).RESULTSOf 262 assessable patients, 74 (29%) achieved tumor regression. Objective occurred 20% the 90 who received alone (complete remission [CR] rate, 2%), 34% 88 (CR 3%), 32% 84 7%). With grade 3 greater myelosuppression 53% gr...